Enfortumab vedotin-ejfv
Enfortumab vedotin-ejfv (pronunciation: en-for-TOO-mab ve-DOE-tin) is a type of Antibody-drug conjugate used in the treatment of certain types of cancer, specifically urothelial carcinoma.
Etymology
The name "Enfortumab vedotin-ejfv" is derived from its components. "Enfortumab" refers to the monoclonal antibody that targets the protein Nectin-4, which is overexpressed in urothelial carcinoma. "Vedotin" refers to the cytotoxic drug that is conjugated to the antibody. The suffix "-ejfv" is a four-letter code used by the World Health Organization to denote specific structural features of the drug.
Usage
Enfortumab vedotin-ejfv is used for the treatment of adults with locally advanced or metastatic urothelial carcinoma who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy.
Mechanism of Action
Enfortumab vedotin-ejfv works by binding to the Nectin-4 protein on the surface of cancer cells. Once bound, the drug is internalized by the cell, where the cytotoxic agent vedotin is released. This agent interferes with the cell's ability to divide and grow, leading to cell death.
Related Terms
- Antibody-drug conjugate
- Monoclonal antibody
- Nectin-4
- Urothelial carcinoma
- PD-1
- PD-L1
- Cytotoxic agent
- Chemotherapy
See Also
External links
- Medical encyclopedia article on Enfortumab vedotin-ejfv
- Wikipedia's article - Enfortumab vedotin-ejfv
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski